A Single Center, Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Rifampicin on Famitinib in Healthy Male Subjects
Latest Information Update: 28 Oct 2022
Price :
$35 *
At a glance
- Drugs Famitinib (Primary) ; Rifampicin (Primary)
- Indications Cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 15 Sep 2022 Results assessing the effect of potent CYP3A4 inducer rifampin on the pharmacokinetics of famitinb published in the Cancer Chemotherapy and Pharmacology
- 27 Sep 2020 Status changed from recruiting to completed.
- 03 Aug 2020 New trial record